Argent Capital Management LLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 102.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 121,275 shares of the company’s stock after purchasing an additional 61,425 shares during the quarter. Argent Capital Management LLC owned 0.26% of Amphastar Pharmaceuticals worth $2,167,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Victory Capital Management Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock worth $100,000 after acquiring an additional 842 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals in the second quarter worth $111,000. Municipal Employees Retirement System of Michigan raised its holdings in shares of Amphastar Pharmaceuticals by 2.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock worth $151,000 after acquiring an additional 230 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Amphastar Pharmaceuticals by 58.2% in the second quarter. BNP Paribas Arbitrage SA now owns 10,545 shares of the company’s stock worth $188,000 after acquiring an additional 3,880 shares during the last quarter. Finally, Thrivent Financial For Lutherans raised its holdings in shares of Amphastar Pharmaceuticals by 7.2% in the second quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock worth $386,000 after acquiring an additional 1,460 shares during the last quarter. 44.14% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Stephen B. Shohet sold 7,862 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $18.04, for a total value of $141,830.48. Following the completion of the transaction, the director now directly owns 31,978 shares in the company, valued at $576,883.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO William J. Peters sold 6,226 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. Insiders sold 194,528 shares of company stock valued at $3,595,253 over the last quarter. Insiders own 11.10% of the company’s stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) opened at $19.26 on Wednesday. The company has a market capitalization of $855.15, a price-to-earnings ratio of 124.00 and a beta of 1.69. Amphastar Pharmaceuticals, Inc. has a 12 month low of $12.05 and a 12 month high of $21.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The firm had revenue of $57.90 million during the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business’s quarterly revenue was down 9.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 earnings per share. equities analysts predict that Amphastar Pharmaceuticals, Inc. will post -0.03 EPS for the current fiscal year.
A number of equities analysts have recently weighed in on AMPH shares. Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. Piper Jaffray Companies reissued a “buy” rating and issued a $19.00 price target on shares of Amphastar Pharmaceuticals in a report on Sunday, September 17th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Thursday, October 19th. Jefferies Group set a $19.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, BMO Capital Markets boosted their price target on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus target price of $20.86.
COPYRIGHT VIOLATION NOTICE: “Argent Capital Management LLC Raises Position in Amphastar Pharmaceuticals, Inc. (AMPH)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/13/argent-capital-management-llc-raises-position-in-amphastar-pharmaceuticals-inc-amph.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.